1 Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006

2 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

3 Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

4 Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

5 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

6 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

7 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

8 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

9 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

10 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

11 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

12 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

13 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

14 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

15 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

16 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

17 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

18 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

19 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

20 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

21 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

22 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

23 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

24 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

25 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

26 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

27 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

28 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

29 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

30 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

31 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

32 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

33 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

34 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

35 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

36 Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.

37 The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

38 Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.

39 The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

40 Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection

41 Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015

42 Molecular epidemiology of hepatitis C virus in Cambodia during 2016–2017

43 The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

44 Epidemiology of Hepatitis C Virus in Bangladeshi General Population

45 Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

46 Alchemy: A web 2.0 real-time quality assurance platform for human immunodeficiency Virus, hepatitis C Virus, and BK Virus quantitation assays

47 Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018.

48 Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.

49 Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity.

50 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

51 Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain.

52 Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis.

53 Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

54 Characterization of the hepatitis C virus epidemic in Pakistan.

55 Strategies to manage hepatitis C virus infection disease burden - volume 3.

56 The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

57 Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

58 Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

59 [Prevalence of hepatitis C virus antibodies in hospital personnel].

60 Extrahepatic Manifestations and Autoantibodies in Patients with Hepatitis C Virus Infection

61 Surveillance and impact of occult hepatitis B virus, SEN virus, and Torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection.

62 Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada

63 Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014.

64 Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index.

65 Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.

66 Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.

67 Clinical implication of the preoperative GSA index in ⁹⁹mTc-GSA scintigraphy in hepatitis C virus-related hepatocellular carcinoma.

68 Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

69 Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia

70 Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation

71 Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.

72 Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study

73 The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C

74 Evolving Epidemiology of Hepatitis C Virus in the United States

75 An Analysis of Hepatitis C Virus–Related Public Inquiries from Health Professionals: 2009–2010

76 Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update

77 Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus

78 HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms

79 Chronic Hepatitis C Virus Infection in Older Adults

80 Performance of Premarket Rapid Hepatitis C Virus Antibody Assays in 4 National Human Immunodeficiency Virus Behavioral Surveillance System Sites

81 Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004

82 Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites

83 Telaprevir for previously untreated chronic hepatitis C virus infection

84 The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

85 Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services

86 A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs

87 Laboratory Diagnostics for Hepatitis C Virus Infection

88 Self-reported hepatitis C virus antibody status and risk behavior in young injectors

89 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis

90 Prospects for Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus

91 Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services

92 The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users

93 A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs

94 Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus

95 Simultaneous Acute Hepatitis B Virus and Hepatitis C Virus Infection Leading to Fulminant Hepatitis and Subsequent Chronic Hepatitis C

96 Notes from the field: risk factors for hepatitis C virus infections among young adults--Massachusetts, 2010

97 The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

98 The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

99 prevalence of hepatitis c virus infection and associated factors among male illicit drug users in cuiabá, mato grosso, brazil

100 noninvasive monitoring of hepatic damage from hepatitis c virus infection

101 predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis c virus genotype 1

Keyword Connections

Journals

Research Groups

Bibliographies